Skip to main content

Advertisement

SpringerLink
Log in

Improvement of quality of life in patients with chronic inflammatory demyelinating polyneuropathy shifting from 16 to 20 % subcutaneous immunoglobulins

  • Letter to the Editor
  • Published:
Neurological Sciences Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Cocito D, Serra G, Falcone Y, Paolasso I (2011) The efficacy of subcutaneous immunoglobulin administration in chronic inflammatory demyelinating polyneuropathy responders to intravenous immunoglobulin. J Peripher Nerv Syst 16:150–152

    Article  PubMed  Google Scholar 

  2. Koller H, Schroeter M, Feischen H, Hartung HP, Kieseier BC (2006) Subcutaneous self-infusions of immunoglobulins as a potential therapeutic regimen in immune-mediated neuropathies. J Neurol 253:1505–1506

    Article  PubMed  Google Scholar 

  3. Lee DH, Linker RA, Paulus W, Schneider-Gold C, Chan A, Gold R (2008) Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 37:406–409

    Article  PubMed  CAS  Google Scholar 

  4. Misbah SA, Baumann A, Fazio R, Dacci P, Schmidt DS, Burton J, Sturzenegger M (2011) A smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglobulin therapy: an open-label proof-of-concept study. J Peripher Nerv Syst 16:92–97

    Article  PubMed  CAS  Google Scholar 

  5. Van den Bergh PY, Hadden RD, Bouche P, Cornblath DR, Hahn A, Illa I, Koski CL, Léger JM, Nobile-Orazio E, Pollard J, Sommer C, van Doorn PA, van Schaik IN (2010) European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society—first revision. Eur J Neurol 17:356–363

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors would like to thank Simona Rigaldo for your dedication and care in the training and preparations of the patient for home-based SCIg therapy, and Barbara Wade for her linguistic advice. This research was funded by the “Compagnia di San Paolo”.

Author information

Authors and Affiliations

  1. Neurologia IV, Department of Neurosciences, University of Turin, Via Cherasco 15, 10126, Turin, Italy

    Dario Cocito, Erdita Peci, Emanuela Spagone & Leonardo Lopiano

  2. Institute of Neurology, Catholic University of Sacred Heart, Rome, Italy

    Ilaria Paolasso

Authors
  1. Dario Cocito
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ilaria Paolasso
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Erdita Peci
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Emanuela Spagone
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Leonardo Lopiano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dario Cocito.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cocito, D., Paolasso, I., Peci, E. et al. Improvement of quality of life in patients with chronic inflammatory demyelinating polyneuropathy shifting from 16 to 20 % subcutaneous immunoglobulins. Neurol Sci 34, 2061–2062 (2013). https://doi.org/10.1007/s10072-013-1426-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-013-1426-5

Keywords

Search

Navigation